Allison Berger
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
Papers in
-
- Ubiquitin and proteasome pathways 34
- Protein Degradation and Inhibitors 11
-
- Multiple Myeloma Research and Treatments 8
- Co-authors
- Jie Yu (8 shared papers)Mark G Manfredi (6 shared papers)Mark Rolfe (4 shared papers)Joshua M. Kaplan (1 shared paper)Anne C. Hart (1 shared paper)Michael A. Milhollen (7 shared papers)Paul Hales (4 shared papers)Bret M. Bannerman (5 shared papers)
- Journals
- Blood (15 papers)Clinical Cancer Research (6 papers)Molecular Cancer Therapeutics (5 papers)Leukemia (3 papers)Cell Metabolism (2 papers)
- Partner nations
- United StatesChinaJapan
In The Last Decade
Allison Berger
55 papers receiving 4.1k citations
Allison Berger's Hit Papers
Peers
Comparison fields: 5 of 113
- Hematology 682
- Oncology 1.3k
- Molecular Biology 3.3k
- Aging 84
- Cancer Research 397
Countries citing papers authored by Allison Berger
This map shows the geographic impact of Allison Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Berger more than expected).
Fields of papers citing papers by Allison Berger
This network shows the impact of papers produced by Allison Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Berger. The network helps show where Allison Berger may publish in the future.
Co-authors
The 25 scholars most cited alongside Allison Berger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Hit paper breakdown → | 2009 | 1697 |
| 2 | 2010 | 439 | |
| 3 | 2010 | 291 | |
| 4 | 2015 | 175 | |
| 5 | 2015 | 153 | |
| 6 | 1998 | 106 | |
| 7 | 2013 | 102 | |
| 8 | 2013 | 99 | |
| 9 | 2011 | 93 | |
| 10 | 2014 | 74 | |
| 11 | 2012 | 72 | |
| 12 | 2018 | 71 | |
| 13 | 2022 | 67 | |
| 14 | 2013 | 64 | |
| 15 | 2019 | 62 | |
| 16 | 2022 | 51 | |
| 17 | 2016 | 50 | |
| 18 | 2015 | 47 | |
| 19 | 2019 | 40 | |
| 20 | 2002 | 40 |
About Allison Berger
Allison Berger is a scholar working on Molecular Biology, Hematology, Oncology, Genetics and Cancer Research, having authored 59 papers that have together received 4.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (34 papers), Protein Degradation and Inhibitors (11 papers), Multiple Myeloma Research and Treatments (8 papers), Cancer-related Molecular Pathways (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Peptidase Inhibition and Analysis (5 papers), Immune Cell Function and Interaction (5 papers) and Microtubule and mitosis dynamics (4 papers). The work is most often cited by research in Hematology (682 citations), Oncology (1.3k citations), Molecular Biology (3.3k citations), Aging (84 citations) and Cancer Research (397 citations). Allison Berger has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Jie Yu, Mark G Manfredi, Mark Rolfe, Joshua M. Kaplan, Anne C. Hart, Michael A. Milhollen, Paul Hales, Bret M. Bannerman, Erik Kupperman and Alexey Valeryevich Danilov. Their work appears in journals such as Blood, Clinical Cancer Research, Molecular Cancer Therapeutics, Leukemia and Cell Metabolism.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.